Newswire (Published: Tuesday, May 30, 2017, Received: Friday, May 26, 2017, 3:59:32 AM CDT)

Word Count: 552

Studies from Tufts University School of Medicine Yield New Information about Prostate Cancer (The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating in Boston, Massachusetts, by NewsRx journalists, research stated, "The 4Kscore Test is a prebiopsy blood test that incorporates four prostate protein biomarkers along with patient clinical information to determine a man's risk for high-grade, aggressive (Gleason greater than or equal to7) prostate cancer. However, some men likely to benefit from the test may be seen in primary care settings where the digital rectal examination (DRE) information is not always obtained."

The news reporters obtained a quote from the research from the Tufts University School of Medicine, "In this study, we assessed the clinical validity of the 4Kscore Test when the DRE information was not included in the algorithm. The Prospective 4Kscore Validation Study enrolled 1012 men scheduled for prostate biopsy across 26 urology practices in the United States. The 4Kscore was calculated for each patient with and without DRE information. The primary outcome was Gleason greater than or equal to7 prostate cancer on prostate biopsy. The contribution of DRE to the predictive accuracy of the test was evaluated by area under the receiver operating curve (AUC-ROC), risk calibration and clinical consequences. High-grade, aggressive prostate cancer was found in 231 (23%) of the 1012 patients. Both versions of the 4Kscore Test, with and without DRE, showed excellent discrimination (AUC=0.821 with DRE and AUC=0.818 without DRE input) and excellent calibration. No clinically significant difference was found between the two versions of the 4Kscore. The 4Kscore Test algorithm, whether DRE findings are available or not, performs well in predicting a man's risk of high-grade, aggressive prostate cancer."

According to the news reporters, the research concluded: "Patients who are suspected of having aggressive prostate cancer can safely have their risk better defined by 4Kscore even if a DRE has not been performed recently."

For more information on this research see: The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. International Journal of Clinical Practice, 2017;():. International Journal of Clinical Practice can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell - www.wiley.com/; International Journal of Clinical Practice - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1742-1241)

Our news correspondents report that additional information may be obtained by contacting S.M. Zappala, Tufts University School of Medicine, Boston, MA, United States. Additional authors for this research include Y. Dong, V. Linder, M. Reeve, D.D. Sjoberg, V. Mathur, R. Roberts, D. Okrongly, J. Newmark, G. Sant and M. Steiner (see also Oncology - Prostate Cancer).

The publisher of the International Journal of Clinical Practice can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

Keywords for this news article include: Boston, Oncology, Massachusetts, United States, Prostate Cancer, Prostatic Neoplasms, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Central America
North America
United States
Americas
Massachusetts
Boston
Malden

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology